Motilal Oswal's research report on Coromandel International
Coromandel International’s (CRIN) experienced a marginal 1% decline in its EBIT during 2QFY24, despite a steep ~31% YoY decline in revenue. Softening of raw material prices and the benefits of backward integration led to EBIT growth of 4% YoY in the Nutrients and Allied business (EBIT contribution: 92%). On the other hand, the Crop Protection business (EBIT contribution: 8%) registered a ~17% YoY decline in EBIT due to pricing pressures. Factoring in its 2QFY24 performance, we maintain our earnings for FY24E/ FY25E. We reiterate our BUY rating on the stock.
Outlook
Factoring in its 2QFY24 performance, we maintain our earnings for FY24E/FY25E. We reiterate our BUY rating on the stock with TP of INR1,300 (at 18x FY25E EPS).
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Budget 2025 News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!